Table of Contents Author Guidelines Submit a Manuscript
International Journal of Surgical Oncology
Volume 2015, Article ID 785793, 9 pages
http://dx.doi.org/10.1155/2015/785793
Clinical Study

Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer

1Division of Surgical Oncology, Department of Surgery, Ottawa Hospital, Ottawa, ON, Canada
2Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada
3Division of Anatomical Pathology, Ottawa Hospital, Ottawa, ON, Canada
4Division of Medical Oncology, Department of Medicine, Ottawa Hospital and Ottawa Hospital Cancer Center, Ottawa, ON, Canada
5Department of Oncology, McMaster University, Hamilton, ON, Canada

Received 23 August 2014; Accepted 26 December 2014

Academic Editor: Kefah Mokbel

Copyright © 2015 Angel Arnaout et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. C. Henderson, “Window of opportunity,” Journal of the National Cancer Institute, vol. 83, no. 13, pp. 894–896, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Kalinsky and D. L. Hershman, “Cracking open window of opportunity trials,” Journal of Clinical Oncology, vol. 30, no. 21, pp. 2573–2575, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. K. B. Wisinski, A. Faerber, S. Wagner et al., “Predictors of willingness to participate in window of opportunity breast trials,” Clinical Medicine and Research, vol. 11, no. 3, pp. 107–112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Glimelius and M. Lahn, “Window of opportunity trials to evaluate clinical activity of new molecular entities in oncology,” Annals of Oncology, vol. 22, no. 8, pp. 1717–1725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Hilton, A. Arnaout, and M. Clemons, “Primary endocrine therapy as an approach for patients with localized breast cancer deemed not to be surgical candidates,” Current Opinion in Supportive and Palliative Care, vol. 8, no. 1, pp. 53–58, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Arnaout, J. F. Boileau, and M. Brackstone, “Surgical considerations in locally advanced breast cancer patients receiving neoadjuvant chemotherapy,” Current Opinion in Supportive and Palliative Care, vol. 8, no. 1, pp. 39–45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. F. C. Wright, J. Zubovits, S. Gardner et al., “Optimal assessment of residual disease after neo-adjuvant therapy for locally advanced and inflammatory breast cancer—clinical examination, mammography, or magnetic resonance imaging?” Journal of Surgical Oncology, vol. 101, no. 7, pp. 604–610, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Lemieux, M. Clemons, L. Provencher et al., “The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers,” Current Oncology, vol. 16, no. 5, pp. 48–57, 2009. View at Google Scholar · View at Scopus
  9. H. Al-Husaini, E. Amir, B. Fitzgerald et al., “Prevalence of overt metastases in locally advanced breast cancer,” Clinical Oncology, vol. 20, no. 5, pp. 340–344, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. P. J. Goodwin, V. Stambolic, J. Lemieux et al., “Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents,” Breast Cancer Research and Treatment, vol. 126, no. 1, pp. 215–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. O. C. Freedman, S. Verma, and M. J. Clemons, “Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?” Cancer Treatment Reviews, vol. 31, no. 1, pp. 1–17, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Singletary, R. Lieberman, N. Atkinson et al., “Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide,” Cancer Epidemiology Biomarkers and Prevention, vol. 9, no. 10, pp. 1087–1090, 2000. View at Google Scholar · View at Scopus
  13. S. E. Singletary, E. N. Atkinson, A. Hoque et al., “Phase II clinical trial of N-(4-hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia,” Clinical Cancer Research, vol. 8, no. 9, pp. 2835–2842, 2002. View at Google Scholar · View at Scopus
  14. S. Niraula, R. J. O. Dowling, M. Ennis et al., “Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study,” Breast Cancer Research and Treatment, vol. 135, no. 3, pp. 821–830, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Hadad, T. Iwamoto, L. Jordan et al., “Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window of opportunity, randomized trial,” Breast Cancer Research and Treatment, vol. 128, no. 3, pp. 783–794, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Demark-Wahnefried, S. L. George, B. R. Switzer et al., “Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer,” Clinical Trials, vol. 5, no. 3, pp. 262–272, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Dowsett, I. Smith, J. Robertson et al., “Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer,” Journal of the National Cancer Institute—Monographs, no. 43, pp. 120–123, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Dowsett, I. E. Smith, S. R. Ebbs et al., “Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer,” Journal of the National Cancer Institute, vol. 99, no. 2, pp. 167–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. R. B. Clarke, I. J. Laidlaw, L. J. Jones, A. Howell, and E. Anderson, “Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status,” British Journal of Cancer, vol. 67, no. 3, pp. 606–611, 1993. View at Publisher · View at Google Scholar · View at Scopus
  20. I. E. Smith, M. Dowsett, S. R. Ebbs et al., “Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5108–5116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. J. Ellis, A. Coop, B. Singh et al., “Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status,” Cancer Research, vol. 63, no. 19, pp. 6523–6531, 2003. View at Google Scholar · View at Scopus
  22. M. J. Ellis, Y. Tao, J. Luo et al., “Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics,” Journal of the National Cancer Institute, vol. 100, no. 19, pp. 1380–1388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. O. C. Freedman, E. Amir, W. Hanna et al., “A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer,” Breast Cancer Research and Treatment, vol. 119, no. 1, pp. 155–161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. D. R. Green and G. Kroemer, “The pathophysiology of mitochondrial cell death,” Science, vol. 305, no. 5684, pp. 626–629, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Bressenot, S. Marchal, L. Bezdetnaya, J. Garrier, F. Guillemin, and F. Plénat, “Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma,” Journal of Histochemistry and Cytochemistry, vol. 57, no. 4, pp. 289–300, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. Jin and W. S. El-Deiry, “Overview of cell death signaling pathways,” Cancer Biology and Therapy, vol. 4, no. 2, pp. 139–163, 2005. View at Google Scholar · View at Scopus
  27. W. R. Duan, D. S. Gamer, S. D. Williams, C. L. Funckes-Shippy, I. S. Spath, and E. A. G. Blomme, “Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts,” Journal of Pathology, vol. 199, no. 2, pp. 221–228, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. M. Gown and M. C. Willingham, “Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3,” Journal of Histochemistry and Cytochemistry, vol. 50, no. 4, pp. 449–454, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. A. R. Resendes, N. Majó, J. Segalés et al., “Apoptosis in normal lymphoid organs from healthy normal, conventional pigs at different ages detected by TUNEL and cleaved caspase-3 immunohistochemistry in paraffin-embedded tissues,” Veterinary Immunology and Immunopathology, vol. 99, no. 3-4, pp. 203–213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Jakob, N. Corazza, E. Diamantis, A. Kappeler, and T. Brunner, “Detection of apoptosis in vivo using antibodies against caspase-induced neo-epitopes,” Methods, vol. 44, no. 3, pp. 255–261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Geisler, S. Detre, H. Berntsen et al., “Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer,” Clinical Cancer Research, vol. 7, no. 5, pp. 1230–1236, 2001. View at Google Scholar · View at Scopus
  32. C. L. Harper-Wynne, N. P. M. Sacks, K. Shenton et al., “Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer,” Journal of Clinical Oncology, vol. 20, no. 4, pp. 1026–1035, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. L.-A. Martin, G. L. S. Davies, M. T. Weigel et al., “Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer,” Breast Cancer Research and Treatment, vol. 123, no. 3, pp. 829–836, 2010. View at Publisher · View at Google Scholar · View at Scopus